Article

Phaco experience in 1,000 pseudoexfoliation patients underlines pearls for success

Pseudoexfoliation is a common disorder that mandates special attention when cataract surgery is indicated, said Bradford J. Shingleton, MD, who delivered the Stephen A. Obstbaum, MD Honored Lecture at ASCRS Glaucoma Day 2007.

Pseudoexfoliation is a common disorder that mandates special attention when cataract surgery is indicated, said Bradford J. Shingleton, MD, who delivered the Stephen A. Obstbaum, MD Honored Lecture at ASCRS Glaucoma Day 2007.

“We need to be aware of pseudoexfoliation, and we need to be wary of it because intraoperative and postoperative complications of cataract surgery are greater in eyes with this disorder,” said Dr. Shingleton, assistant clinical professor, Harvard Medical School, and clinical instructor of ophthalmology, Tufts University School of Medicine, Boston.

Dr. Shingleton told attendees that he considers pseudoexfoliation the most common problematic issue in his practice that embraces both cataract and glaucoma. He reported findings from analyses of his single surgeon, consecutive series of phacoemulsification in 1,000 patients (1,500 eyes) with pseudoexfoliation and reviewed considerations for surgical success.

His retrospective analyses included comparisons of outcomes of cataract surgery in patients with unilateral pseudoexfoliation who underwent bilateral phacoemulsification, patients with pseudoexfoliation with and without glaucoma, and patients with pseudoexfoliation and glaucoma undergoing combined surgery versus phacoemulsification alone.

Regarding IOP outcomes, the results showed IOP is lower after cataract surgery in eyes without pseudoexfoliation than in affected eyes. The pseudoexfoliation eyes achieve a greater mean decrease in IOP and have stable glaucoma medication requirements until 3 to 5 years. Pseudoexfoliation eyes with and without glaucoma both show sustained IOP reduction after cataract surgery, while combined surgery can afford an even greater reduction in IOP. The findings from his review also highlighted the role of zonular weakness rather than capsule tears as the greatest risk factor for intraoperative complications.

Outlining keys for success, Dr. Shingleton emphasized the importance of identifying patients at high risk preoperatively by looking for frank phacodinesis and more subtly, anterior depth asymmetry between eyes. Intraoperatively, it is important to achieve free nucleus rotation and use phaco chop because it avoids directing aspiration forces to the peripheral capsule. Dr. Shingleton advocated liberal use of capsular retractors or capsule tension segments, and he emphasized suturing the capsule tension ring if there is concern about progressive zonule weakness. Implantation of an acrylic posterior chamber IOL may be preferred because it may minimize phimosis, and surgeons should be prepared to convert to planned extracapsular or pars plana lensectomy/virectomy approaches as necessary.

Postoperatively, patients need to be followed carefully to detect and treat anterior capsular fibrosis early in order to reduce progressive capsular contraction that can result in IOL subluxation, he said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.